Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

Defense Secretary Pete Hegseth summoned hundreds of U.S. military officials to an in-person meeting Tuesday to announce ...

At ASTRO, Artera presented clinical validation data on its prostate cancer test in an Asian population,and showed how the test may complement gene expression-based approaches.

Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

A genetic test could guide the use of hormone therapy for men with recurrent prostate cancer after surgery, according to data ...

The PRIME trial tested whether the dynamic contrast enhancement sequence in multiparametric MRI is truly necessary to improve significant prostate cancer ...

When a slow-growing prostate cancer showed signs of progressing, Dave Donaldson's enlarged prostate almost got in the way of the most effective treatment. But the team approach to urology at Fox Chase ...

Baystreet.ca News Commentary – Major biotechnology companies are presenting multi-cancer detection data and breakthrough clinical results at the European Society for Medical Oncology ...

(UroToday.com) The 2025 ASTRO annual meeting featured a biomarker breakthroughs prostate cancer session and a discussant presentation by Dr. Alan Dal Pra. Dr. Dal Pra noted that amongst the six ...